Pharmaceutical compounds

1. A compound which is a benzimidazole of formula (I):

wherein:

A is phenyl or 6-membered heteroaryl, each of which is unsubstituted or substituted by 1, 2 or 3 groups Q;

Y is a single bond, —O—, —C(═O)—N(R 2 )—, or —(CH 2 ) p —;

each L is independently C 1-3 alkylene;

R 1 is linear or branched C 1-6 alkyl, which is unsubstituted or substituted by 1, 2 or 3 groups Q;

each Z is independently —N(R 2 ) 2 or —OR 2 ;

each R 2 is independently hydrogen or C 1-4 alkyl;

m is 0 or 1;

n is 1, 2, or 3;

p is 1 or 2; and

Q is halo, nitro, —CN, OH, C 1-6 alkoxy, C 1-6 hydroxyalkyl, C 1-6 alkylthio, C 1-6 haloalkyl, C 1-4 haloalkoxy, —CO 2 R′″, —NR′″ 2 , —SR′″, —S(═O)R′″ or —S(═O) 2 R′″, wherein each R′″ is independently selected from H and C 1-6 alkyl;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein R 1 is a linear or branched C 3-6 alkyl.

3. A compound according to claim 1 wherein, in formula (I):

A is phenyl group or a pyridyl group which is unsubstituted or substituted by 1, 2, or 3 halo groups;

Y is a single bond, —O—, —C(═O)—NH—, or —CH 2 —;

L is —CH 2 —;

R 1 is a linear or branched C 4-6 alkyl group which is unsubstituted or substituted by 1, 2, or 3 halo groups;

Z is —NH 2 ;

m is 0 or 1; and

n is 1, 2 or 3.

4. A compound according to claim 1 wherein the benzimidazole of formula (I) has the following formula (a):

wherein

G is N or CH

Y is a single bond, —O—, —C(═O)—NH—, or —CH 2 —;

n is 1, 2 or 3; and

R 3 is H or —CH 2 NH 2 .

5. A compound according to claim 3 wherein, in formula (I), A is an unsubstituted phenyl group or an unsubstituted pyridyl group.

6. A compound according to claim 1 which is selected from

1′-((5-(aminomethyl)-1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)spiro[cyclopentane-1,3′-pyrrolo[2,3-c]pyridin]-2′(1′H)-one;

1′-((5-(aminomethyl)-1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)spiro[cyclopropane-1,3′-indolin]-2′-one;

1′-((1-isopentyl-IH-benzo[d]imidazol-2-yl)methyl)spiro[cyclopropane-1,3′-indolin]-2′-one;

1′-((5-(aminomethyl)-1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)spiro[cyclopentane-1,3′-indolin]-2′-one;

1′-((1-isopentyl-IH-benzo[d]imidazol-2-yl)methyl)spiro[cyclopentane-1,3′-indolin]-2′-one;

1′-((5-(aminomethyl)-1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)spiro[cyclobutane-1,3′-indolin]-2′-one;

1′-((1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)spiro[cyclobutane-1,3′-indolin]-2′-one;

4-((5-(aminomethyl)-1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)spiro[benzo[b][1,4]oxazine-2,1′-cyclopropan]-3(4H)-one;

4-((1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)spiro[benzo[b][1,4]oxazine-2,1′-cyclopropan]-3(4H)-one;

1′-((5-(aminomethyl)-1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)-1′H-spiro[cyclopropane-1,3′-quinolin]-2′(4′H)-one;

1′-((1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)-1′H-spiro[cyclopropane-1,3′-quinolin]-2′(4′H)-one;

1′-((5-(aminomethyl)-1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)-1′H-spiro[cyclopentane-1,3′-quinolin]-2′(4′H)-one;

1′-((1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)-1′H-spiro[cyclopentane-1,3′-quinolin]-2′(4′H)-one; and

1-((1-isopentyl-1H-benzo[d]imidazol-2-yl)methyl)spiro[benzo[e][1,4]diazepine-3,1′-cyclopropane]-2,5(1H,4H)-dione;

and the pharmaceutically acceptable salts thereof.

7. A pharmaceutical composition which comprises a compound as defined in claim 1 , and a pharmaceutically acceptable carrier or diluent.

8. A product containing:

(a) a compound as defined in claim 1 ; and

(b) one or more further therapeutic agents.

9. A product according to claim 8 , wherein the further therapeutic agent is:

(i) a RSV nucleocapsid (N)-protein inhibitor;

(ii) another protein inhibitor;

(iii) an anti-RSV monoclonal antibody;

(iv) an immunomodulating toll-like receptor compound;

(v) another respiratory virus anti-viral; and/or

(vi) an anti-inflammatory compound.

10. A pharmaceutical composition which comprises (a) a compound as defined in claim 1 , and (b) one or more further therapeutic agents, together with a pharmaceutically acceptable carrier or diluent.